NCT03987815View on ClinicalTrials.gov

Neoadjuvant Nivolumab for Operable Esophageal Carcinoma

PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

July 31, 2022

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Nivolumab

Nivolumab

Trial Locations (1)

06351

RECRUITING

Jong-Mu Sun, Seoul

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Samsung Medical Center

OTHER